A Subject-blind, Investigator-blind, Randomized, Placebo-controlled, First-in-human Study Evaluating the Safety/Tolerability, Pharmacokinetics, Effect on Transglutaminase 2 Expression, and Occupancy of Single Ascending Intravenous and Subcutaneous Doses of UCB7858 in Healthy Subjects
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 08 Dec 2017
At a glance
- Drugs UCB 7858 (Primary) ; UCB 7858 (Primary)
- Indications Autoimmune disorders
- Focus Adverse reactions; First in man
- Sponsors UCB
- 11 Sep 2017 Planned End Date changed from 1 Sep 2017 to 25 Jan 2018.
- 11 Sep 2017 Planned primary completion date changed from 1 Sep 2017 to 25 Jan 2018.
- 11 Sep 2017 Status changed from recruiting to active, no longer recruiting.